111 related articles for article (PubMed ID: 1161374)
1. Screening procedures for neuroblastoma: false-negative results.
Johnsonbaugh RE; Cahill R
Pediatrics; 1975 Aug; 56(2):267-70. PubMed ID: 1161374
[TBL] [Abstract][Full Text] [Related]
2. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma.
Tuchman M; Ramnaraine ML; Woods WG; Krivit W
Pediatrics; 1987 Feb; 79(2):203-5. PubMed ID: 3808793
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of vanillylmandellic acid in neuroblastoma.
Aydin GB; Kutluk MT; Yalcin B; Varan A; Akyuz C; Buyukpamukcu M
Pediatr Hematol Oncol; 2010 Sep; 27(6):435-48. PubMed ID: 20578806
[TBL] [Abstract][Full Text] [Related]
4. Value of random urinary homovanillic acid and vanillylmandelic acid levels in the diagnosis and management of patients with neuroblastoma: comparison with 24-hour urine collections.
Tuchman M; Morris CL; Ramnaraine ML; Bowers LD; Krivit W
Pediatrics; 1985 Feb; 75(2):324-8. PubMed ID: 3969335
[TBL] [Abstract][Full Text] [Related]
5. Urinary VMA, dopamine and the likelihood of neuroblastoma: a preferred way of reporting laboratory results?
Sies CW; Florkowski CM; Sullivan M; Mackay R; George PM
Ann Clin Biochem; 2006 Jul; 43(Pt 4):300-5. PubMed ID: 16824281
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma screening: labeling of HVA and VMA for stable isotope dilution gas chromatography-mass spectrometry.
Gleispach H; Huber E; Fauler G; Kerbl R; Urban C; Leis HJ
Nutrition; 1995; 11(5 Suppl):604-6. PubMed ID: 8748233
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous measurement of VMA and HVA in 24-hour urine samples.
Harr R
Clin Lab Sci; 1991; 4(4):237-41. PubMed ID: 10149424
[TBL] [Abstract][Full Text] [Related]
8. The LaBrosse VMA spot test revisited.
Ong M; Dupont CL
J Pediatr; 1975 Feb; 86(2):238-40. PubMed ID: 1111687
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients.
Strenger V; Kerbl R; Dornbusch HJ; Ladenstein R; Ambros PF; Ambros IM; Urban C
Pediatr Blood Cancer; 2007 May; 48(5):504-9. PubMed ID: 16732582
[TBL] [Abstract][Full Text] [Related]
10. Urinary vanillylmandelic acid and homovanillic acid levels in randomly-sampled urine for the mass screening of neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
Jpn J Clin Oncol; 1990 Sep; 20(3):268-70. PubMed ID: 2255102
[TBL] [Abstract][Full Text] [Related]
11. Interchangeability between 24-hour collection and single spot urines for vanillylmandelic and homovanillic acid levels in the diagnosis of neuroblastoma.
Cangemi G; Barco S; Reggiardo G; Viscardi E; Di Cataldo A; Garaventa A; Melioli G; Conte M
Pediatr Blood Cancer; 2013 Dec; 60(12):E170-2. PubMed ID: 23813598
[TBL] [Abstract][Full Text] [Related]
12. Cases of neuroblastoma missed by the mass screening programs.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J; Kawai T
Pediatr Res; 1989 Dec; 26(6):603-7. PubMed ID: 2602040
[TBL] [Abstract][Full Text] [Related]
13. Effects of mass screening for neuroblastoma and the presumptive natural history of this tumor.
Takeda T; Shimada M; Iizuka S; Takasugi N
Prog Clin Biol Res; 1994; 385():383-8. PubMed ID: 7972235
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of vanillylmandelic acid in random and 24-hour urine collections.
Riddhimat R; Prabhant C; Sirisali K; Tangvarasithichai O; Poosiri A
J Med Assoc Thai; 1990 May; 73(5):239-43. PubMed ID: 2212910
[TBL] [Abstract][Full Text] [Related]
15. Determination of homovanillic acid and vanillylmandelic acid in neuroblastoma screening by stable isotope dilution GC-MS.
Fauler G; Leis HJ; Huber E; Schellauf C; Kerbl R; Urban C; Gleispach H
J Mass Spectrom; 1997 May; 32(5):507-14. PubMed ID: 9180052
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of the VMA test strip.
Helson L; Bethune V; Schwartz MK
Pediatrics; 1973 Jan; 51(1):153. PubMed ID: 4684442
[No Abstract] [Full Text] [Related]
17. Screening for neuroblastoma in the northern region of England. Laboratory aspects.
Seviour JA; McGill AC; Craft AW; Parker L; Bell S; Cole M; Smith J; Hawkins E; Brown J; Dale GA
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):332-6. PubMed ID: 1456399
[TBL] [Abstract][Full Text] [Related]
18. [Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society].
Sawada T; Nagahara N; Ohi R; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Ohkawa H; Tunoda A
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2319-26. PubMed ID: 2260868
[TBL] [Abstract][Full Text] [Related]
19. [Sensitivity and specificity of the determination of urinary catecholamines and their acid metabolites in the diagnosis of neuroblastoma in children].
Horsmans Y; Desager JP; Harvengt C
Bull Cancer; 1990; 77(10):985-9. PubMed ID: 2249018
[TBL] [Abstract][Full Text] [Related]
20. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors.
LaBrosse EH; Com-Nougué C; Zucker JM; Comoy E; Bohuon C; Lemerle J; Schweisguth O
Cancer Res; 1980 Jun; 40(6):1995-2001. PubMed ID: 7371035
[No Abstract] [Full Text] [Related]
[Next] [New Search]
